📰 Receptor Type News
Receptor Type News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Receptor Type. Real-time updates on events, politics, business and more.
March 30, 2022
/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...
February 3, 2022
/PRNewswire/ -- The newly published report titled "Global Cannabinoid Derived Pharmaceutical Market – By Trends, Industry Competition Analysis, Pipeline...
February 3, 2022
JERSEY CITY, N.J., Feb. 3, 2022 /PRNewswire/ -- The newly published report titled "Global Cannabinoid Derived Pharmaceutical Market - By Trends, Industry Competition Analysis, Pipeline Analysis
July 15, 2021
Share this article Share this article SUZHOU, China, July 14, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005. TST005 is the second bi-functional anti-PD-L1 and TGF-β trap fusion protein en...
June 28, 2021
Investigating the prognosis value of EDNRA expression and its correlation with immune infiltrates in patients with stomach adenocarcinoma
April 20, 2021
Share this article Share this article SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of its IND for TST005 from US FDA for initiating Phase I clinical trial of its bi-functional anti-PD-L1/TGF-β antibody. TST005, is a bi-functional anti-PD-L1 and TGF-�...
April 16, 2021
Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting News provided by Share this article Share this article SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functional anti-PD-L1 and TGF-β trap fusion protein, i...